Baricitinib Effectiveness and Patient Impressions in Routine Clinical Practice: 12-month Results from a Prospective Observational Real-world Study

Main Article Content

Justin Ko
Stanford University, Palo Alto, USA

Tiffany Mayo
University of Alabama in Birmingham, Birmingham, USA

Crystal Aguh
Johns Hopkins Medicine, Baltimore, USA

Susan Ball
Eli Lilly and Company, Indianapolis, USA

Angelina Sontag
Eli Lilly and Company, Indianapolis, USA

Firas Dabbous
PPD Evidera, Thermo Fisher Scientific, Waltham, USA

Mary Kate Ladd
PPD Evidera, Thermo Fisher Scientific, Waltham, USA

Klaudia Kornalska
PPD Evidera, Thermo Fisher Scientific, Waltham, USA

Najwa Somani
Eli Lilly and Company, Indianapolis, USA

Jerry Shapiro
New York University, New York, USA

Keywords

Alopecia Areata

References

1. Wyrwich KW, et al. Br J Dermatol. 2020;183:1065-1072.

2. Wyrwich KW, et al. Am J Clin Dermatol. 2020;21:725-732.

3. Mostaghimi A, et al. J Am Acad Dermatol. 2024;91:729-732.

4. Guy W (ed). ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: US Department of Health, Education, and Welfare, 1976.

Article Sidebar

PDF
Published
2025-11-10
DOI: https://doi.org/10.25251/z118e008

Article Details

How to Cite
1.
Baricitinib Effectiveness and Patient Impressions in Routine Clinical Practice: 12-month Results from a Prospective Observational Real-world Study. J of Skin. 2025;9(6):s668. doi:10.25251/z118e008
Issue
Vol. 9 No. 6 (2025): November 2025 Issue
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>